How Pharma can Overcome Barriers to CGT Diagnostic Testing
Diagnostic testing allows pharmaceutical companies to identify the right patients for cell and gene therapies to maximize therapeutic and commercial success. However, ensuring access to diagnostic testing is complex. Our experts provide insights on barriers pharma face and how to overcome them.
Typically, cell and gene therapies (CGTs) tackle rare diseases with a relatively small, restricted patient population. Yet, the industry continues to thrive and make important advancements in many disease areas. As such, pharmaceuticals are increasing their focus in this field.
However, CGTs are expensive both in terms of development and treatment. This is likely to cause problems down the line as the industry grows, especially with regards to reimbursement. So, what can companies developing CGTs do to maximize therapeutic and commercial success?
